Boston Scientific Corporation $BSX Shares Sold by Polen Capital Management LLC

Polen Capital Management LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 28.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 4,019,552 shares of the medical equipment provider’s stock after selling 1,578,734 shares during the period. Boston Scientific comprises about 1.6% of Polen Capital Management LLC’s holdings, making the stock its 23rd biggest holding. Polen Capital Management LLC’s holdings in Boston Scientific were worth $383,264,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $26,000. Colonial Trust Co SC raised its stake in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the last quarter. Bangor Savings Bank lifted its holdings in Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in Boston Scientific during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a research report on Wednesday, May 27th. Finally, Canaccord Genuity Group dropped their price objective on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $85.92.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 9,800 shares of company stock valued at $554,012 in the last ninety days. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $47.22 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $70.18 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The stock’s 50-day moving average is $56.68 and its two-hundred day moving average is $75.14. Boston Scientific Corporation has a 1-year low of $46.91 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.